-
公开(公告)号:EP3199627A1
公开(公告)日:2017-08-02
申请号:EP15843390.4
申请日:2015-09-24
发明人: TORIGOE, Toshihiko , ATSUYAMA, Eri , OTAKA, Hironori , NAKANO, Kazue , LI, Dongliang , TOJI, Shingo , ASANO, Takuya , HORIBE, Ryota , HIROHASHI, Yoshihiko , SATO, Noriyuki , SAITO, Tsuyoshi
IPC分类号: C12N15/00 , A61K35/76 , A61K39/00 , A61K48/00 , A61P35/00 , A61P37/04 , C07K7/06 , C12N5/10 , C12N15/09 , C07K14/82
CPC分类号: C07K14/4703 , A61K35/76 , A61K39/00 , A61K39/0011 , A61K48/00 , A61K2039/5158 , A61K2039/572 , C07K7/06 , C07K14/70539 , C07K14/82 , C07K16/18 , C07K16/30 , C12N5/0634 , C12N5/0638 , C12N5/10 , C12N15/00 , C12N15/09 , C12N2510/00 , G01N33/57496 , G01N2333/4704
摘要: The object is to provide a tumor antigen peptide that is specifically presented on a cancer and a cancer stem cell, and a pharmaceutical composition, etc. that is useful for the prevention and/or treatment of a cancer and contains the above peptide as an active ingredient.
The above object has been accomplished by providing a BORIS-derived partial peptide belonging to isoform A or C or subfamily 5 or 6, a polynucleotide encoding the peptide, a pharmaceutical composition containing the above as an active ingredient, and an agent for the prevention and/or treatment of a cancer, the agent containing the above as an active ingredient and inducing CTLs.摘要翻译: 本发明的目的在于提供可用于癌症的预防和/或治疗的含有上述肽作为有效成分的癌症和癌干细胞上特异性表达的肿瘤抗原肽和药物组合物等 成分。 上述目的通过提供属于同种型A或C或亚科5或6的BORIS衍生的部分肽,编码该肽的多核苷酸,含有上述作为活性成分的药物组合物,以及用于预防和 /或治疗癌症,包含上述作为活性成分并诱导CTL的试剂。